Literature DB >> 1660525

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity.

K Peppel1, D Crawford, B Beutler.   

Abstract

Using a multistep polymerase chain reaction method, we have produced a construct in which a cDNA sequence encoding the extracellular domain of the human 55-kD tumor necrosis factor (TNF) receptor is attached to a sequence encoding the Fc portion and hinge region of a mouse IgG1 heavy chain through an oligomer encoding a thrombin-sensitive peptide linker. This construct was placed downstream from a cytomegalovirus promoter sequence, and expressed in Chinese hamster ovary cells. A secreted protein, capable of binding TNF and inactivating it, was produced by the transfected cells. Molecular characterization revealed that this soluble version of the TNF receptor was dimeric. Moreover, the protein could be quantitatively cleaved by treatment with thrombin. However, the monovalent extracellular domain prepared in this way has a greatly reduced TNF inhibitory activity compared with that of the bivalent inhibitor. Perhaps because of its high affinity for TNF, the chimeric protein is far more effective as a TNF inhibitor than are neutralizing monoclonal antibodies. This molecule may prove very useful as a reagent for the antagonism and assay of TNF and lymphotoxin from diverse species in health and disease, and as a means of deciphering the exact mechanism through which TNF interacts with the 55-kD receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660525      PMCID: PMC2119031          DOI: 10.1084/jem.174.6.1483

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.

Authors:  H Loetscher; E J Schlaeger; H W Lahm; Y C Pan; W Lesslauer; M Brockhaus
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

2.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors.

Authors:  R A Smith; M Kirstein; W Fiers; C Baglioni
Journal:  J Biol Chem       Date:  1986-11-15       Impact factor: 5.157

5.  A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.

Authors:  T Kohno; M T Brewer; S L Baker; P E Schwartz; M W King; K K Hale; C H Squires; R C Thompson; J L Vannice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

Authors:  P Seckinger; S Isaaz; J M Dayer
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

7.  Multimeric structure of the tumor necrosis factor receptor of HeLa cells.

Authors:  R A Smith; C Baglioni
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

8.  A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

Authors:  H Engelmann; D Aderka; M Rubinstein; D Rotman; D Wallach
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

9.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences.

Authors:  Z Dembic; H Loetscher; U Gubler; Y C Pan; H W Lahm; R Gentz; M Brockhaus; W Lesslauer
Journal:  Cytokine       Date:  1990-07       Impact factor: 3.861

10.  The AU-rich sequences in the 3' untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids.

Authors:  K Peppel; J M Vinci; C Baglioni
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

View more
  93 in total

1.  Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.

Authors:  Qing-Hui Zhou; Rachita Sumbria; Eric Ka-Wai Hui; Jeff Zhiqiang Lu; Ruben J Boado; William M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

2.  An Fc-Small Molecule Conjugate for Targeted Inhibition of the Adenosine 2A Receptor.

Authors:  Po-Yuan Hsiao; Jay H Kalin; Im-Hong Sun; Mohammed N Amin; Ying-Chun Lo; Meng-Jung Chiang; John Giddens; Polina Sysa-Shah; Kathleen Gabrielson; Lai-Xi Wang; Jonathan D Powell; Philip A Cole
Journal:  Chembiochem       Date:  2016-08-26       Impact factor: 3.164

3.  Constitutive synthesis of tumor necrosis factor in the thymus.

Authors:  B P Giroir; T Brown; B Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

Review 4.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

Review 5.  Infectious complications associated with monoclonal antibodies and related small molecules.

Authors:  Edsel Maurice T Salvana; Robert A Salata
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

6.  Profile of Bruce A. Beutler.

Authors:  Sandeep Ravindran
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

7.  Immune regulation by CD52-expressing CD4 T cells.

Authors:  Ban-Hock Toh; Tin Kyaw; Peter Tipping; Alex Bobik
Journal:  Cell Mol Immunol       Date:  2013-08-12       Impact factor: 11.530

8.  Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.

Authors:  Mohammed F Shamji; Priscilla Hwang; Robert W Bullock; Samuel B Adams; Dana L Nettles; Lori A Setton
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-07       Impact factor: 3.368

9.  Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology.

Authors:  Catharina Steentoft; Sergey Y Vakhrushev; Hiren J Joshi; Yun Kong; Malene B Vester-Christensen; Katrine T-B G Schjoldager; Kirstine Lavrsen; Sally Dabelsteen; Nis B Pedersen; Lara Marcos-Silva; Ramneek Gupta; Eric Paul Bennett; Ulla Mandel; Søren Brunak; Hans H Wandall; Steven B Levery; Henrik Clausen
Journal:  EMBO J       Date:  2013-04-12       Impact factor: 11.598

10.  TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis.

Authors:  P Mukherjee; B Wu; L Mayton; S-H Kim; P D Robbins; P H Wooley
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.